Key facts
- This page summarizes Sukumar Nagendran's Form 4 filing for Solid Biosciences Inc. (SLDB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 13 Jun 2024, 16:08.
Sukumar Nagendran - 11 Jun 2024 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)
- Reporting relationship
- Director
- Issuer ticker
- SLDB
- Reported as of
- 11 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Jun 2024, 16:08:01 UTC
- Prior SEC filing
- 04 Jan 2024
- Next SEC filing
- 03 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ by David Tyronne Howton as attorney-in-fact for Sukumar Nagendran
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sukumar Nagendran filed Form 4 for Solid Biosciences Inc. (SLDB) on 13 Jun 2024.
Change
- Previous filing in this sequence was filed on 04 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SLDB
transaction
Derivative
Director Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +34,400
- Change %
- Price
- $0.000000
- Shares after
- 34,400
- Date
- 11 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 34,400
- Exercise price
- $7.51
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option was granted on June 11, 2024 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.